Streetbeat News

Analyst Ratings

DLTR

Citigroup analyst Paul Lejuez maintains a Neutral rating on Dollar Tree (NASDAQ:DLTR) and lowers the price target from $120 to $64.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:44 pm

MRO

Citigroup analyst Scott Gruber maintains a Neutral rating on Marathon Oil and lowers the price target from $29 to $28.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:40 pm

RIGL

HC Wainwright & Co. has reiterated its Buy rating for Rigel Pharmaceuticals, maintaining a price target of $57. This suggests confidence in Rigel's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:38 pm

YEXT

Yext, Inc. (NYSE:YEXT) has been upgraded to Buy by Needham analyst Ryan MacDonald, with a price target of $8. The upgrade follows better-than-expected Q2 EPS results and positive FY25 revenue guidance. The Hearsay acquisition is expected to drive margin expansion despite initial dilution, and cross-sell opportunities could boost growth in FY26.

Portfolio Pulse from Nabaparna Bhattacharya

September 05, 2024 | 6:37 pm

KREF

KKR Real Estate Finance shares rose following an upgrade by Keefe, Bruyette & Woods from Market Perform to Outperform, with a price target increase from $11.5 to $13.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:36 pm

GHRS

HC Wainwright & Co. has reiterated its Buy rating on GH Research (NASDAQ:GHRS) and maintained a price target of $40, indicating confidence in the company's potential.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:36 pm

HES

Citigroup analyst Scott Gruber maintains a Neutral rating on Hess (NYSE:HES) and lowers the price target from $160 to $145.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:36 pm

CRC

Citigroup analyst Scott Gruber maintains a Buy rating on California Resources (NYSE:CRC) and raises the price target from $63 to $65.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:34 pm

NVO

NVS

Goldman Sachs has downgraded Novartis AG (NYSE:NVS) from Buy to Neutral, citing limited near-term innovation catalysts and a premium valuation compared to the European Biopharma sector. Despite ongoing share buybacks, significant stock gains are not expected until mid-2025.

Portfolio Pulse from Vandana Singh

September 05, 2024 | 6:34 pm

VC

Wolfe Research analyst Emmanuel Rosner has assumed coverage of Visteon (NASDAQ:VC) with a Peer Perform rating.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 6:33 pm